Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs
Covered in this story
Analyst targets on Alphabet Inc. (Class A)
- KeyBanc Capital Markets: $338 → $435 by Oct 2027 · Overweight via Finbold
- JPMorgan: $338 → $420 by Oct 2027 · Overweight via Finbold
- RBC Capital Markets: $338 → $425 by Oct 2027 via Finbold
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $GOOGL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alphabet Inc. (Class A) →Dalsna Finance is currently tracking 46 stories mentioning Alphabet Inc. (Class A), the earliest published 16 Jul 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.